NCT03260491 2026-03-05
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Active not recruiting
Clinical Trials
4 trialsNCT04619004 2026-01-23
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Active not recruiting
NCT04676477 2025-06-22
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Active not recruiting
NCT05338970 2025-01-31
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Daiichi Sankyo
Phase 3 Active not recruiting